全文获取类型
收费全文 | 35167篇 |
免费 | 6270篇 |
国内免费 | 103篇 |
专业分类
耳鼻咽喉 | 181篇 |
儿科学 | 1056篇 |
妇产科学 | 2105篇 |
基础医学 | 2203篇 |
口腔科学 | 325篇 |
临床医学 | 17869篇 |
内科学 | 4921篇 |
皮肤病学 | 227篇 |
神经病学 | 1980篇 |
特种医学 | 500篇 |
外国民族医学 | 1篇 |
外科学 | 2189篇 |
综合类 | 627篇 |
一般理论 | 37篇 |
预防医学 | 4179篇 |
眼科学 | 329篇 |
药学 | 953篇 |
中国医学 | 9篇 |
肿瘤学 | 1849篇 |
出版年
2024年 | 92篇 |
2023年 | 868篇 |
2022年 | 215篇 |
2021年 | 534篇 |
2020年 | 807篇 |
2019年 | 496篇 |
2018年 | 1396篇 |
2017年 | 1568篇 |
2016年 | 1709篇 |
2015年 | 1848篇 |
2014年 | 1973篇 |
2013年 | 2527篇 |
2012年 | 1572篇 |
2011年 | 1893篇 |
2010年 | 1626篇 |
2009年 | 1890篇 |
2008年 | 1692篇 |
2007年 | 1729篇 |
2006年 | 1692篇 |
2005年 | 1585篇 |
2004年 | 1543篇 |
2003年 | 1431篇 |
2002年 | 1322篇 |
2001年 | 592篇 |
2000年 | 362篇 |
1999年 | 565篇 |
1998年 | 792篇 |
1997年 | 889篇 |
1996年 | 818篇 |
1995年 | 732篇 |
1994年 | 546篇 |
1993年 | 456篇 |
1992年 | 331篇 |
1991年 | 312篇 |
1990年 | 315篇 |
1989年 | 261篇 |
1988年 | 217篇 |
1987年 | 185篇 |
1986年 | 187篇 |
1985年 | 206篇 |
1984年 | 178篇 |
1983年 | 170篇 |
1982年 | 157篇 |
1981年 | 177篇 |
1980年 | 128篇 |
1979年 | 142篇 |
1978年 | 108篇 |
1977年 | 116篇 |
1976年 | 113篇 |
1972年 | 103篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
ABSTRACTThis work collates data from the analysis of complex mixtures analysed in STRmix during routine no-suspect volume crime work. It interrogates the upload rate for these types of mixtures and which component of the profile has been able to be interpreted for upload. The number of profiles giving multiple uploads and the amount of replicate PCR analysis has been collated. 相似文献
2.
3.
4.
5.
6.
7.
8.
9.
Hazel B Breitz Richard E Wendt Michael S Stabin Sui Shen William D Erwin Joseph G Rajendran Janet F Eary Lawrence Durack Ebrahim Delpassand William Martin Ruby F Meredith 《Journal of nuclear medicine》2006,47(3):534-542
166Ho-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonate (DOTMP) is a tetraphosphonate molecule radiolabeled with 166Ho that localizes to bone surfaces. This study evaluated pharmacokinetics and radiation-absorbed dose to all organs from this beta-emitting radiopharmaceutical. METHODS: After two 1.1-GBq administrations of 166Ho-DOTMP, data from whole-body counting using a gamma-camera or uptake probe were assessed for reproducibility of whole-body retention in 12 patients with multiple myeloma. The radiation-absorbed dose to normal organs was estimated using MIRD methodology, applying residence times and S values for 166Ho. Marrow dose was estimated from measured activity retained after 18 h. The activity to deliver a therapeutic dose of 25 Gy to the marrow was determined. Methods based on region-of-interest (ROI) and whole-body clearance were evaluated to estimate kidney activity, because the radiotracer is rapidly excreted in the urine. The dose to the surface of the bladder wall was estimated using a dynamic bladder model. RESULTS: In clinical practice, gamma-camera methods were more reliable than uptake probe-based methods for whole-body counting. The intrapatient variability of dose calculations was less than 10% between the 2 tracer studies. Skeletal uptake of 166Ho-DOTMP varied from 19% to 39% (mean, 28%). The activity of 166Ho prescribed for therapy ranged from 38 to 67 GBq (1,030-1,810 mCi). After high-dose therapy, the estimates of absorbed dose to the kidney varied from 1.6 to 4 Gy using the whole-body clearance-based method and from 8.3 to 17.3 Gy using the ROI-based method. Bladder dose ranged from 10 to 20 Gy, bone surface dose ranged from 39 to 57 Gy, and doses to other organs were less than 2 Gy for all patients. Repetitive administration had no impact on tracer biodistribution, pharmacokinetics, or organ dose. CONCLUSION: Pharmacokinetics analysis validated gamma-camera whole-body counting of 166Ho as an appropriate approach to assess clearance and to estimate radiation-absorbed dose to normal organs except the kidneys. Quantitative gamma-camera imaging is difficult and requires scatter subtraction because of the multiple energy emissions of 166Ho. Kidney dose estimates were approximately 5-fold higher when the ROI-based method was used rather than the clearance-based model, and neither appeared reliable. In future clinical trials with 166Ho-DOTMP, we recommend that dose estimation based on the methods described here be used for all organs except the kidneys. Assumptions for the kidney dose require further evaluation. 相似文献
10.